Form 4 for KLRS Kalaris Therapeutics, Inc.
Accepted 2022-01-24 00:00:00 ET · period of report 2022-01-20 · accession 0000899243-22-003002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-01-24 | 2022-01-20 | KLRS | Sinha Vikas | See Remarks, Dir | S - Sale | $8.75 | -6,450 | 859.0K | -0.7% | -$56.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-01-20 | S | D | 6,450 | $8.75 | 858,957 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.49 to $9.09. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |